Table 3.
Comparison between men and women for mean side effects.
| Amisulpride (n = 52) | ||||
|---|---|---|---|---|
| Men (n = 25) | Women (n = 27) | p value | Effect size | |
| Neurologic side effects (UKU) | 0.37 (0.56) | 0.31 (0.38) | 0.376 | 0.126 |
| Sexual side effects (UKU) | 0.26 (0.42) | 0.37 (0.48) | 0.051 | 0.243 |
| BMI increase (kg/m2) | 0.90 (1.14) | 1.34 (2.27) | 0.111 | 0.242 |
| Glucose level (mmol/L) | 5.08 (0.62) | 5.15 (0.82) | 0.426 | 0.096 |
| Prolactin level (mIU/L) | 920.3 (553.0) | 1869.2 (1212.5) | <0.001* | 1.013 |
| Aripiprazole (n = 51) | ||||
|---|---|---|---|---|
| Men (n = 39) | Women (n = 12) | p value | Effect size | |
| Neurologic side effects (UKU) | 0.46 (0.44) | 0.49 (0.40) | 0.699 | 0.070 |
| Sexual side effects (UKU) | 0.34 (0.43) | 0.23 (0.44) | 0.114 | 0.255 |
| BMI increase (kg/m2) | 0.64 (1.28) | −0.04 (1.46) | 0.016 | 0.454 |
| Glucose level (mmol/L) | 5.71 (1.45) | 5.47 (1.63) | 0.366 | 0.161 |
| Prolactin level (mIU/L) | 265.9 (328.4) | 307.4 (162.3) | 0.216 | 0.139 |
| Olanzapine (n = 41) | ||||
|---|---|---|---|---|
| Men (n = 29) | Women (n = 12) | p value | Effect size | |
| Neurologic side effects (UKU) | 0.34 (0.47) | 0.38 (0.46) | 0.643 | 0.086 |
| Sexual side effects (UKU) | 0.18 (0.35) | 0.34 (0.54) | 0.059 | 0.388 |
| BMI increase (kg/m2) | 1.48 (1.27) | 0.24 (1.25) | <0.001* | 0.981 |
| Glucose level (mmol/L) | 5.40 (1.76) | 5.00 (0.68) | 0.032 | 0.026 |
| Prolactin level (mIU/L) | 376.6 (223.5) | 667.7 (542.1) | 0.001* | 0.845 |
Data are mean values over all timepoints of the follow-up period with SD. Differences significant with α = 0.05 are shown in bold. p Values with asterisk (*) remained significant after FDR correction. Cohen’s d was used to calculate effect sizes.
n number in the total sample, BMI body mass index.